Individuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard care.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Conventional type 1 dendritic cells (cDC1) in cancer immunity
Biology Direct Open Access 01 November 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Amaria, R. N. et al. Lancet Oncol. 20, e378–e389 (2019).
Topalian, S. L. et al. Science 367, eaax0182 (2020).
Versluis, J. M. et al. Nat. Med. 26, 475–484 (2020).
Blank, C. U. et al. Nat. Med. 24, 1655–1661 (2018).
Eggermont, A. M. M. et al. NEJM Evidence 1, EVIDoa2200214 (2022).
Patel, S. et al. Ann. Oncol. 33, S808–S869 (2022).
Eggermont, A. M. M. et al. N. Engl J. Med. 378, 1789–1801 (2018).
Amaria, R. N. et al. Nature 611, 155–160 (2022).
Huang, A. C. et al. Nat. Med. 25, 454–461 (2019).
Reijers, I. L. M. et al. Nat. Med. 28, 1178–1188 (2022).
Dummer, R. et al. Nat. Med. 27, 1789–1796 (2021).
Dummer, R. et al. Ann. Oncol. 33, S1406 (2022).
Rozeman, E. A. et al. Lancet Oncol. 20, 948–960 (2019).
Tetzlaff, M. T. et al. Ann. Oncol. 29, 1861–1868 (2018).
Menzies, A. M. et al. Nat. Med. 27, 301–309 (2021).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
C.G. declares funding from and has an advisory role at Merck Sharp & Dhome (MSD), Novartis, NeraCare, Bristol-Meyers Squibb (BMS) and Philogen. R.D. has an advisory role at Novartis, MSD, BMS, Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, Catalym, Second Genome, Regeneron, Alligator, T3 Pharma, MaxiVAX SA, Pfizer and touchIME. T.A. has an advisory role at CeCaVa, Novartis, NeraCare, BMS, Pierre Fabre, Sanofi, SkylineDx and iFIT. R.A. declares funding from Novartis. P.A. has an advisory role at BMS, Roche-Genentech, MSD, Novartis, Merck Serono, Pierre Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Nektar, Italfarmaco, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTx, Replimmune and Bayer. B.D. declares funding from BMS, Fabre Oncology, Novartis, Almirall and Sun Pharma. A.E. declares funding from Agenus, BioInvent, BioNTech, Brenus, CatalYm, Ellipses, Epics, Galecto, GenOway, IO Biotech, IQVIA, Merck & Co./MSD, Pfizer, Sairopa, Sellas, SkylineDX, TigaTX and Trained Immunity TX. A.H. has an advisory role at Amgen, BMS, MerckPfizer, MSD/Merck, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme, Novartis Pharma, Eisai, Immunocore, Replimune, Seagen, IO Biotech, Dermagnostix, Incyte, NeraCare, Highlight Therapeutics, Huya Biosciences and Kyowa Kirin. C.H. declares funding from BMS, Novartis, Amgen, Almirall, Pierre Fabre and Sanofi. R.K. has an advisory role at Abbvie, Amgen, BMS, Celgene, Galderma, Jannsen, MSD, Novartis, Roche and UCB. C.L. declares funding from BMS, Roche, MSD, Novartis, Amgen, Merck Serono, Sanofi, Pierre Fabre, Pfizer, Incyte, Avantis, InflaRx and Jazz Pharmaceuticals. M.M. has an advisory role at Novartis, BMS, Sanofi, Pierre Fabre and MSD. A.M. has an advisory role at BMS, MSD, Novartis, Roche, Pierre-Fabre and QBiotics. O.M. has an advisory role at BMS, Roche-Genentech, MSD, Novartis, Merck Serono, Pierre Fabre, AstraZeneca and Immunocore. P.N. has an advisory role at MSD, Novartis, Merck, BMS, Pfizer, Immunocore and Ipsen. S.P. declares funding from BMS, Foghorn Therapeutics, Ideaya, InxMed, Lyvgen Biopharma, Novartis, Provectus Biopharmaceuticals, Seagen, Syntrix Bio, TriSalus Life Sciences, Advance Knowledge in Healthcare, Cardinal Health, Castle Biosciences, Delcath, Immatics, Immunocore and Replimune. C.R. has an advisory role at BMS, Roche, Pierre Fabre, Novartis, Sanofi, Pfizer, MSD and AstraZeneca. D.S. has an advisory role at Merck Serono, Amgen, Immunocore, 4SC, Pierre Fabre, Pfizer, Philogen, Regeneron, Nektar, Novartis, Sanofi, Ultimovacs, Haystack, Astra Zeneca, Daiichi Sankyo, Agenus, InFlarX, Agenus, Replimune, Erasca, SunPharma, Immatics, Neracare, Seagen and Bioalta. P.L. has an advisory role at BMS, Merck, Novartis, GlaxoSmithKline (GSK), Amgen, Chugai, PierreFabre, NeraCare, Roche and OncologyEducationCanada. R.S. has an advisory role at MetaOptima Technology, F. Hoffmann-La Roche, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, MSD, NeraCare, Amgen, BMS, Myriad Genetics and GSK. H.T. has an advisory role at BMS, Novartis, Merck, Genentech, GSK, EMD Serono, Eisai, Dragonfly Therapeutics, RAPT Therapeutics, Boxer Capital, Karyopharm, Lovance, Jazz Pharmaceuticals and Medicenna. C.B. has an advisory role at MSD, Novartis, BMS, Roche, GSK, AstraZeneca, Pfizer, Lilly, GenMAB, Pierre Fabre, Third Rock ventures, NanoString and 4SC. G.L. has an advisory role at Agenus, Amgen, Array Biopharma, Boehringer Ingelheim International, BMS, Evaxion, Hexal AG, Highlight Therapeutics, Innovent Biologics, MSD, Novartis, OncoSec, PHMR, Pierre Fabre, Provectus, Qbiotics and Regeneron. All other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Garbe, C., Dummer, R., Amaral, T. et al. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice. Nat Med 29, 1310–1312 (2023). https://doi.org/10.1038/s41591-023-02336-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02336-1
This article is cited by
-
Schwierig zu therapierende Melanome
hautnah dermatologie (2024)
-
Conventional type 1 dendritic cells (cDC1) in cancer immunity
Biology Direct (2023)
